Ocular Therapeutix宣布,其研究性疗法Axpaxli在代号为Sol-1的临床研究中展现出良好的安全性特征。数据显示,该药物在试验过程中总体耐受性良好,且未观察到任何与治疗相关的眼部严重不良事件(SAEs)。这一积极结果为进一步评估Axpaxli的疗效和安全性提供了有力支持。
Ocular Therapeutix宣布,其研究性疗法Axpaxli在代号为Sol-1的临床研究中展现出良好的安全性特征。数据显示,该药物在试验过程中总体耐受性良好,且未观察到任何与治疗相关的眼部严重不良事件(SAEs)。这一积极结果为进一步评估Axpaxli的疗效和安全性提供了有力支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.